Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262782 | 0.85 | SMN1; SMN2 (0.43) | KDM4ETSHRGAASMN1; SMN2LMNA | |
| SCHEMBL4096065 | 0.83 | TSHR (0.44) | KDM4ETSHRSMN1; SMN2LMNAPTGS1 | |
| Hydrochloric Acid SCHEMBL261292 | 0.83 | SMN1; SMN2 (0.43) | KDM4ETSHRGAASMN1; SMN2LMNA | |
| SCHEMBL26926134 | 0.82 | LMNA (0.44) | KDM4ETSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL14845471 | 0.82 | KDM4E (0.38) | KDM4ETSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL6018683 | 0.81 | MEN1 (0.45) | KDM4ETSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL19815469 | 0.81 | KDM4E (0.46) | KDM4ETSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL20543421 | 0.81 | KDM4E (0.37) | KDM4EGAASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL262849 | 0.81 | KDM4E (0.44) | KDM4ETSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL2357873 | 0.80 | TSHR (0.38) | KDM4ETSHRGAASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069318-B1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| EP-2069322-B1 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8044076-B2 | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20100087495-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069318-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008035239-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | S1PR1, S1PR3, S1PR2 | KDM4E 1389/4885TSHR 325/4885GAA 4812/4885 |
| US-20100087495-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | IL2, CD47, CD74 | KDM4E 855/4885TSHR 2492/4885GAA 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.